1. Home
  2. CTMX vs TECX Comparison

CTMX vs TECX Comparison

Compare CTMX & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • TECX
  • Stock Information
  • Founded
  • CTMX 2008
  • TECX 2019
  • Country
  • CTMX United States
  • TECX United States
  • Employees
  • CTMX N/A
  • TECX N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • TECX
  • Sector
  • CTMX Health Care
  • TECX
  • Exchange
  • CTMX Nasdaq
  • TECX Nasdaq
  • Market Cap
  • CTMX 349.6M
  • TECX 387.1M
  • IPO Year
  • CTMX 2015
  • TECX 2018
  • Fundamental
  • Price
  • CTMX $1.93
  • TECX $15.06
  • Analyst Decision
  • CTMX Strong Buy
  • TECX Buy
  • Analyst Count
  • CTMX 4
  • TECX 6
  • Target Price
  • CTMX $5.13
  • TECX $79.17
  • AVG Volume (30 Days)
  • CTMX 2.4M
  • TECX 502.6K
  • Earning Date
  • CTMX 11-06-2025
  • TECX 11-06-2025
  • Dividend Yield
  • CTMX N/A
  • TECX N/A
  • EPS Growth
  • CTMX 263.20
  • TECX N/A
  • EPS
  • CTMX 0.49
  • TECX N/A
  • Revenue
  • CTMX $141,100,000.00
  • TECX N/A
  • Revenue This Year
  • CTMX N/A
  • TECX N/A
  • Revenue Next Year
  • CTMX N/A
  • TECX N/A
  • P/E Ratio
  • CTMX $3.98
  • TECX N/A
  • Revenue Growth
  • CTMX 18.01
  • TECX N/A
  • 52 Week Low
  • CTMX $0.40
  • TECX $13.70
  • 52 Week High
  • CTMX $3.10
  • TECX $61.07
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 41.17
  • TECX 31.98
  • Support Level
  • CTMX $1.90
  • TECX $15.92
  • Resistance Level
  • CTMX $2.16
  • TECX $18.61
  • Average True Range (ATR)
  • CTMX 0.13
  • TECX 1.60
  • MACD
  • CTMX -0.01
  • TECX -0.46
  • Stochastic Oscillator
  • CTMX 7.50
  • TECX 0.49

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: